Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $47.4 million.

  • Lineage Cell Therapeutics' Non-Current Assets fell 23.82% to $47.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.4 million, marking a year-over-year decrease of 23.82%. This contributed to the annual value of $62.2 million for FY2024, which is 0.57% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Non-Current Assets stood at $47.4 million, which was up 0.90% from $47.0 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Non-Current Assets high stood at $63.5 million for Q1 2023, and its period low was $4.9 million during Q4 2021.
  • Over the past 3 years, Lineage Cell Therapeutics' median Non-Current Assets value was $62.4 million (recorded in 2024), while the average stood at $59.8 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Non-Current Assets spiked by 1,003.08% in 2023, and later fell by 24.77% in 2025.
  • Lineage Cell Therapeutics' Non-Current Assets (Quarterly) stood at $4.9 million in 2021, then grew by 16.44% to $5.7 million in 2022, then soared by 1,003.08% to $62.6 million in 2023, then declined by 0.57% to $62.2 million in 2024, then declined by 23.82% to $47.4 million in 2025.
  • Its Non-Current Assets was $47.4 million in Q3 2025, compared to $47.0 million in Q2 2025 and $61.8 million in Q1 2025.